@NurseGomer @sassy_classy_rn Folks in the migraine spectrum: 🙏 please talk with your HCP about biologics. If they won’t, find a qualified HCP who will. Understood financials is a problem for many, and. Most *decent* patent-holders have programs to help. I
片頭痛情報の続き：2021現在、FDA承認または臨床試験中のCGRPモノクローナル抗体 fremanezumab, erenumab, eptinezumab, galcanezumab. #541 https://t.co/6cKD5y8S4y
Immunogenicity of biologic therapies for migraine: a review of current evidence. "...evidence is increasing that immunogenicity rates of biologic therapies for migraine are low, and adverse events related to ADAs are rare." https://t.co/RZ5wxOk3eY
RT @NeuroPsychBMC: Immunogenicity of biologic therapies for migraine: a review of current evidence https://t.co/Y4oMDRvnzO